Degenerative diseases of the retina, including macular degeneration and retinal degeneration, are among the leading causes of progressive vision loss worldwide. These conditions are characterized by damage to photoreceptors, retinal pigment epithelium, and microvascular structures, ultimately leading to impaired visual function and, in advanced cases, irreversible blindness.
At a biological level, these diseases are not driven by a single factor. They involve a combination of:
Chronic inflammation /Oxidative stress /Microvascular insufficiency /Loss of retinal cells /Impaired cellular communication and regeneration
Modern research shows that stem cell-based therapies offer a promising regenerative approach, as they can reduce inflammation, support retinal cells, and promote tissue repair .
Case Study 1: Macular Degeneration
Patient Story: Alejandro, 48 Years Old (Spain)
Alejandro, a 48-year-old patient from Spain, was diagnosed with early progressive macular degeneration. Unlike typical age-related cases, his condition developed earlier, likely due to a combination of genetic predisposition, chronic oxidative stress, and lifestyle factors.
At first, the symptoms were subtle — slight blurring of central vision and difficulty focusing on fine details. Over time, however, these changes became more pronounced.
Reading became difficult. Night vision worsened. Faces lost clarity.
By the time he sought regenerative therapy, Alejandro described his vision as “fragmented” — with a central distortion that interfered with both professional and daily activities.
Clinical Findings Before Treatment
Reduced central visual acuity /Early macular thinning (OCT imaging) /Decreased retinal sensitivity /Signs of microvascular insufficiency /Increased oxidative stress markers
At this stage, the disease reflected not only structural retinal damage but also metabolic and vascular dysfunction within the macular region.
Regenerative Treatment Strategy
Alejandro underwent a targeted retinal regeneration protocol, combining:
Human Mesenchymal Stem Cells (hMSCs) → anti-inflammatory effect, secretion of neuroprotective and angiogenic factors
Microvascular Endothelial Cells → restoration of retinal microcirculation and oxygen delivery
Normal Human Astrocytes → support of neural environment, stabilization of retinal signaling and metabolic balance
This combination was selected to address the three critical components of macular degeneration:
-
Cell survival (photoreceptors and retinal cells)
-
Microvascular supply
-
Neural support and signaling
MSCs are known to release growth factors and reduce inflammation, creating a protective environment for retinal cells , while endothelial cells improve perfusion and astrocytes stabilize neural networks.
Clinical Progress and Results
Early Phase (First 4–6 Weeks)
Alejandro reported improved visual comfort and reduced eye fatigue. Contrast sensitivity began to improve, especially in low-light conditions.
Intermediate Phase (3–5 Months)
Visual acuity improved by 25–30%/ Central distortion reduced significantly /Retinal sensitivity increased by 30–40% / OCT imaging showed stabilization of macular thinning /Microcirculation improved by ~40%
These changes suggest restoration of both vascular and cellular function within the macula.
Advanced Phase (6–9 Months)
Visual clarity improved by 40–50% overall /Reading ability restored without strain /Improved color perception and contrast /Stabilization of disease progression
FREE MEDICAL CONSULTATION
Case Study 2: Retinal Degeneration
Patient Story: Wei Zhang, 61 Years Old (China)
Wei Zhang, a 61-year-old patient from China, had been diagnosed with progressive retinal degeneration (retinitis pigmentosa–like condition) for over 8 years.
His condition began with night blindness and peripheral vision loss, gradually progressing toward tunnel vision. By the time of treatment, his visual field was significantly restricted.
He described his experience as “living inside a narrowing frame.”
Clinical Condition Before Therapy
Severely reduced peripheral vision / Night vision impairment /Decreased photoreceptor activity /Thinning of retinal layers (OCT)/ Reduced retinal electrical activity (ERG)/ Microvascular compromise
This stage reflects photoreceptor loss combined with neurodegeneration and vascular insufficiency.
Regenerative Treatment Strategy
Wei Zhang received a comprehensive retinal regeneration protocol, including:
-
hMSCs → neuroprotection, anti-inflammatory signaling, prevention of photoreceptor apoptosis
-
Microvascular Endothelial Cells → restoration of retinal blood supply and oxygenation
-
Normal Human Astrocytes → support for neuronal survival, regulation of retinal microenvironment
Scientific data shows that MSCs can reduce retinal inflammation, inhibit photoreceptor death, and promote regeneration through paracrine signaling .
Clinical Progress and Results
Early Phase (First 4–6 Weeks)
Wei Zhang reported improved adaptation to low light and slight expansion of peripheral awareness.
Intermediate Phase (3–6 Months)
Peripheral vision improved by 20–30%/ Night vision improved by 30–40% /ERG activity increased by ~25% /Retinal thickness stabilized /Reduction in progression rate
Advanced Phase (6–9 Months)
Peripheral vision expanded by 40–45% /Visual field stabilization /Improved spatial orientation and mobility /Slowing of degenerative progression
In retinal degeneration, the therapeutic goal is not only restoration but preservation of remaining photoreceptors and neural pathways.
Regenerative therapy works by:
Protecting existing cells /Enhancing microcirculation /Activating repair signaling pathways /Supporting neural connectivity
Why This Approach Works
The success of regenerative ophthalmology lies in its multi-layered mechanism:
-
hMSCs → reduce inflammation and provide neuroprotection
-
Endothelial cells → restore blood supply
-
Astrocytes → stabilize neural networks and metabolic balance
Together, they recreate a functional retinal microenvironment, allowing the eye to recover, adapt, and maintain vision.
